OakChart

Iovance Biotherapeutics Inc

IOVAHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:09 AM ET

8.13+0.05 (0.62%)
2026-11-11 16:09 CET
Market cap
3,738.25 USD m
Revenue, TTM
378.92 USD m
Net income, TTM
-220.53 USD m
Free cash flow, TTM
-216.06 USD m
EPS diluted, TTM
-0.52
P/E
-
Compare

Price

IOVA against its 20, 50 and 200-day averages
2050200beat
5.0010.0015.0039.1M78.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IOVAclose 8.1320-day 11.3650-day 11.37200-day 6.068.13

47.1% under 15.37 on 21 Oct 2026. Last 15 sessions, 95.3% high to low

Profile

IOVA
52-week range, 46% of the way up
2.0815.37

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

IndexRUT
Employees975
IPOSep 01, 2009
Beta0.85
ATR, 14d0.99
Rel volume0.49
Short float16.19%
Insider own12.96%
Inst own56.67%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.76B
Enterprise Value3.43B
Income-220.53M
Sales378.92M
Book/sh1.76
Cash/sh0.81
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees975
IPOSep 01, 2009

Ratios

P/E-
Forward P/E-
PEG-
P/S9.93
P/B4.63
P/C10.00
P/FCF-
EV/EBITDA-
EV/Sales9.05
Quick Ratio4.67
Current Ratio5.20
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.52
EPS next Y-0.09
EPS next Q-0.04
EPS this Y64.84%
EPS next Y75.22%
EPS next 5Y-
EPS past 3/5Y23.93% 10.23%
Sales past 3/5Y- -
EPS Y/Y TTM56.78%
Sales Y/Y TTM51.31%
EPS Q/Q80.53%
Sales Q/Q80.07%
EarningsNov 05 BMO
EPS/Sales Surpr.40.55% 4.73%

Ownership

Insider Own12.96%
Insider Trans0.00%
Inst Own56.67%
Inst Trans5.62%
ROA-23.26%
ROE-29.11%
ROIC-25.78%
Gross Margin43.45%
Oper. Margin-60.81%
Profit Margin-58.20%
SMA20-28.43%
SMA50-28.52%
SMA20034.13%
Trades-

Technical

Shs Outstand462.54M
Shs Float402.69M
Short Float16.19%
Short Ratio4.02
Short Interest65.19M
52W High15.37 -47.10%
52W Low2.08 290.87%
Volatility9.94% 8.66%
ATR (14)0.99
RSI (14)33.81
Beta0.85
Rel Volume0.49
Avg Volume16.24M
Volume1,148,984

Performance

Perf Week-6.55%
Perf Month-43.93%
Perf Quarter24.69%
Perf Half Y122.13%
Perf YTD197.80%
Perf Year206.79%
Perf 3Y104.79%
Perf 5Y-65.40%
Perf 10Y6.97%
Recom1.50
Target Price14.50
Prev Close8.08
Price8.13
Change %0.62%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 24, 2026ResumedGGoldmanBuy$15+84.5%
Feb 25, 2026UpgradeCCitizensMkt Perform → Mkt Outperform$5-38.5%
Jul 15, 2025DowngradeGGoldmanNeutral → Sell$1-87.7%
May 16, 2025DowngradeUUBSBuy → Neutral$2-75.4%
May 12, 2025DowngradeTTruistBuy → Hold
May 09, 2025DowngradeCCitizens JMPMkt Outperform → Mkt Perform
Oct 24, 2024InitiatedUUBSBuy$17+109.1%
Jul 29, 2024DowngradePPiper SandlerOverweight → Neutral$19 → $10+23.0%
Nov 20, 2023InitiatedGGoldmanBuy$12+47.6%
Sep 18, 2023ReiteratedBBarclaysOverweight$40 → $18+121.4%

Peers

Mkt cap
TickerCompanyMkt cap
OBXObsidian Therapeutics Inc814.48M
IMTXImmatics N.V986.85M
IMCRImmunocore Holdings plc ADR1.64B
LYELLyell Immunopharma Inc426.80M
REPLReplimune Group Inc2.17B
LEGNLegend Biotech Corp ADR3.73B
IBRXImmunityBio Inc7.07B
AUTLAutolus Therapeutics plc ADR339.35M
BMYBristol-Myers Squibb Co125.56B
MRKMerck & Co Inc359.58B

Insider trading

latest 14 of 35
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Roche Corleen M.Chief Financial OfficerNov 06 '26Option Exercise0.0012,500041,257Nov 10 05:00 PM
Vogt Frederick GInterim CEO & General CounselSep 08 '26Option Exercise0.0015,6260602,085Sep 10 05:01 PM
BILINSKY IGORChief Operating OfficerSep 08 '26Option Exercise0.007,8130146,050Sep 10 05:00 PM
Puri Raj K.Chief Regulatory OfficerSep 08 '26Option Exercise0.009,7660260,842Sep 10 05:00 PM
Vogt Frederick GInterim CEO & General CounselSep 01 '26Option Exercise0.0041,6690604,161Sep 03 05:02 PM
Puri Raj K.Chief Regulatory OfficerSep 01 '26Option Exercise0.005,4700253,584Sep 03 05:02 PM
BILINSKY IGORChief Operating OfficerSep 01 '26Option Exercise0.008,7890142,709Sep 03 05:00 PM
Kirby Daniel GordonChief Commercial OfficerAug 10 '26Option Exercise0.0010,0010156,947Aug 12 05:30 PM
Roche Corleen M.Chief Financial OfficerAug 06 '26Option Exercise0.0049,995049,995Aug 10 05:30 PM
Vogt Frederick GInterim CEO & General CounselJun 05 '26Option Exercise0.0015,6250569,130Jun 09 05:03 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 05 '26Option Exercise0.007,8130144,087Jun 09 05:01 PM
Puri Raj K.Chief Regulatory OfficerJun 05 '26Option Exercise0.009,7660251,957Jun 09 05:00 PM
BILINSKY IGORChief Operating OfficerJun 05 '26Option Exercise0.007,8130137,896Jun 09 05:00 PM
Vogt Frederick GInterim CEO & General CounselJun 01 '26Option Exercise0.0041,6680571,206Jun 03 05:02 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B

News

latest 14 of 206
  • Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA Geode Adds More (Stocktwits)
  • Iovance Beats With Record Quarter And 60% Gross Margin, But Reaffirmed Guide Implies A Flat Fourth Quarter (Earnings Whispers) -11.03%
  • Iovance Biotherapeutics: Q3 Earnings Snapshot (Associated Press)
  • Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates (GlobeNewswire)
  • SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus (Stocktwits) -5.42%
  • Loading…
  • SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3 (Stocktwits) -11.30%
  • IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says Selling Is Not Done Whats Driving The Fall? (Stocktwits) -35.45%
  • Iovance stock falls after lung cancer trial data disappoints (Investing.com)
  • Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) (GlobeNewswire)
  • Why Did IOVA Stock Jump Over 10% After-Hours Today? (Stocktwits)
  • Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy (GlobeNewswire)
  • Iovance's Raised Outlook Implies A Bigger Third Quarter Than Wall Street Models (Earnings Whispers)
  • Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 (GlobeNewswire) +5.81%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.050-0.084-0.050121.47115.989
2026Q22026-08-06-0.110-0.134-0.10599.3187.838
2026Q12026-05-07-0.190-0.154-0.18971.4377.849
2025Q42026-02-24-0.180-0.175-0.17786.7180.7110
2025Q32025-11-06-0.250-0.258-0.25167.4672.8511
2025Q22025-08-07-0.330-0.283-0.33459.9567.1011
2025Q12025-05-08-0.360-0.242-0.36049.3282.3712
2024Q42025-02-27-0.260-0.268-0.25873.6972.1114
2024Q32024-11-07-0.280-0.299-0.27658.5653.7913
2024Q22024-08-08-0.340-0.354-0.34131.1124.5912
2024Q12024-05-09-0.420-0.424-0.4240.722.0313
2023Q42024-02-28-0.450-0.431-0.4550.481.4413
2023Q32023-11-07-0.460-0.455-0.4630.474.5013
2023Q22023-08-08-0.470-0.498-0.4750.243.919
2023Q12023-05-09-0.500-0.567-0.5020.000.2211
2022Q42023-02-28-0.640-0.637-0.6390.000.0014

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.590-1.498-1.5890.000.00
2020FY-1.880-1.846-1.8770.000.00
2021FY-2.230-2.149-2.2310.000.00
2022FY-2.490-2.484-2.4860.000.00
2023FY-1.890-1.871-1.8891.194.42
2024FY-1.280-1.295-1.284164.07162.47
2025FY-1.090-1.080-1.090263.5257.73
2026FY--0.383--419.2
2027FY--0.095--594.14
2028FY-0.276--886.35
2029FY-0.320--1,134
2030FY-0.593--1,464

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-05942128.58124.2134.86
2026Q4S2026-10-30960129.13125.76134.86
2026Q4S2026-10-28960128.44124.17134.86
2026Q4S2026-10-22970128.44124.17134.86
2026Q4S2026-10-20970128.45124.17134.86
2026Q4S2026-10-09980128.45124.17134.86
2026Q4S2026-10-07980126.6113.3134.86
2026Q4S2026-09-29980126.35113.3134.86
2026Q4S2026-09-28980125.91113.3134.86
2026Q4S2026-09-23971121.24102.8134.86
2026Q4S2026-08-24871120.67102.8134.86
2026Q4S2026-08-20880127.66102.8165.26
2026Q4S2026-08-19880127.67102.8165.3
2026Q4S2026-08-14870125.71102.8165.3

Estimate history

EPS, annual-1.411-1.27-1.589-1.877-2.231-2.486-1.889-1.284-1.094-0.5195
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.276-0.258-0.36-0.334-0.251-0.177-0.189-0.105-0.049
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000001.189164.07263.502378.92
Period201720182019202020212022202320242025TTM
Sales, quarterly58.55573.69449.32459.95267.45586.71171.4399.313121.469
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual73.165123.416126.412146.875157.005187.812256.136305.252411.938462.543
Period201720182019202020212022202320242025MRQ
Shares, quarterly304.62305.252333.934341.919385.462411.938438.107452.971462.543
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue378.92263.50164.071.190.000.000.000.000.00
Cost of Goods Sold Incl. D&A214.29209.12146.4033.1321.1413.988.718.120.96
Gross Profit164.6454.3817.67-31.94-21.14-13.98-8.71-8.12-0.96
Selling, General and Administrative Excl. Other395.07452.59412.95428.62377.74328.72253.22198.75127.30
Research and Development241.88300.27282.34344.08294.78259.04201.73166.0299.83
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-230.44-398.21-395.28-460.56-398.88-342.70-261.94-206.87-128.26
Interest Expense------0.000.000.00
Unusual Expense0.005.140.000.000.000.000.00--
Net Income Before Taxes-221.78-393.05-375.00-447.52-395.89-342.25-259.58-197.56-123.58
Income Taxes-1.24-2.07-2.83-3.480.000.000.000.000.00
Consolidated Net Income-220.53-390.98-372.18-444.04-395.89-342.25-259.58-197.56-123.58
Net Income From Continuing Operations-220.53-390.98-372.18-444.04-395.89-342.25-259.58-197.56-123.58
Net Income-220.53-390.98-372.18-444.04-395.89-342.25-259.58-197.56-123.58
EPS (Recurring)-0.48-1.08-1.28-1.89-2.49-2.23-1.88-1.59-1.27
EPS (Basic, Before Extraordinaries)-0.52-1.09-1.28-1.89-2.49-2.23-1.88-1.59-1.27
EPS (Diluted)-0.52-1.09-1.28-1.89-2.49-2.23-1.88-1.59-1.27
EBITDA-186.56-350.89-351.67-427.43-377.74-328.72-253.22-198.75-127.30
Non-Operating Income (Expense)8.6010.3120.2713.042.980.452.369.324.68
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense36.8648.6486.6049.4784.0269.7740.8924.2820.03
Price To Sales Ratio17.833.7013.071,607.75-----
Gross Margin43.4520.6410.77-2,686.12-----
Operating Margin-60.81-151.12-240.92-38,734.99-----
Net Margin-58.20-148.38-226.84-37,345.42-----
Shares Outstanding462.54411.94305.25256.14187.81157.00146.87126.41123.42
Market Capitalization3,738.253,738.252,255.382,080.611,008.602,995.206,806.283,493.081,090.05

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue121.4799.3171.4386.7167.4559.9549.3273.69
Cost of Goods Sold Incl. D&A57.5253.0951.0452.6347.4862.9055.4051.68
Gross Profit63.9446.2220.3934.0819.97-2.95-6.0822.01
Selling, General and Administrative Excl. Other87.9198.12101.44107.60109.73110.82115.14108.59
Research and Development49.3458.8562.4971.2075.1779.3676.8872.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.97-51.91-81.04-73.52-89.76-113.77-121.22-86.58
Interest Expense-0.00------
Unusual Expense0.000.000.000.005.140.000.000.00
Net Income Before Taxes-21.66-48.69-79.71-71.72-93.66-109.67-118.00-77.00
Income Taxes0.61-1.37-0.670.18-2.401.99-1.841.56
Consolidated Net Income-22.27-47.31-79.05-71.90-91.25-111.66-116.16-78.56
Net Income From Continuing Operations-22.27-47.31-79.05-71.90-91.25-111.66-116.16-78.56
Net Income-22.27-47.31-79.05-71.90-91.25-111.66-116.16-78.56
EPS (Recurring)-0.05-0.11-0.19-0.18-0.24-0.33-0.36-0.26
EPS (Basic, Before Extraordinaries)-0.05-0.11-0.19-0.18-0.25-0.33-0.36-0.26
EPS (Diluted)-0.05-0.11-0.19-0.18-0.25-0.33-0.36-0.26
EBITDA-13.55-41.50-70.63-60.88-78.05-101.84-110.16-74.89
Non-Operating Income (Expense)2.313.221.331.741.244.103.229.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.359.278.909.349.4011.8018.1024.47
Price To Sales Ratio17.835.765.144.223.152.385.0613.75
Gross Margin52.6446.5428.5539.3129.61-4.92-12.3229.87
Operating Margin-19.73-52.26-113.46-84.79-133.06-189.78-245.76-117.48
Net Margin-18.33-47.64-110.66-82.92-135.28-186.25-235.51-106.60
Shares Outstanding462.54452.97438.11411.94385.46341.92333.93305.25
Market Capitalization3,738.251,857.451,445.991,083.72785.22574.371,091.832,255.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments296.98323.78279.87471.85504.41629.44307.08468.52145.37
Short Term Receivables82.4569.340.150.000.000.000.000.000.00
Inventories51.6851.5210.370.000.000.000.000.000.00
Other Current Assets11.5812.3817.467.273.556.669.416.853.92
Total Current Assets442.69457.02307.85479.12507.96636.10316.49475.37149.29
Net Property, Plant & Equipment177.01164.28176.54178.25169.92113.9219.232.682.45
Total Investments and Advances5.986.3666.436.4397.675.535.450.000.00
Intangible Assets279.32282.40229.26------
Other Assets8.170.370.270.191.7812.923.482.763.63
Total Assets913.17910.43780.35663.98777.33768.46344.65480.82155.37
Short Term Debt Incl. Current Port. of LT Debt5.0412.907.7812.595.066.287.250.000.00
Accounts Payable22.1627.5133.1226.6027.3813.5115.572.741.23
Other Current Liabilities111.1681.9469.4152.3056.7735.0716.2711.668.36
Total Current Liabilities138.36122.34110.3191.4889.2054.8739.0814.409.60
Long Term Debt44.4045.3768.0872.8666.4745.384.250.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities31.8332.3117.35------
Other Liabilities0.000.000.000.000.0011.712.350.230.30
Total Liabilities214.59200.02195.74164.34155.67111.9645.6814.639.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.010.01
Common Equity698.58710.40584.61499.63621.66656.49298.97466.19145.47
Total Shareholders Equity698.58710.40584.61499.64621.66656.50298.97466.19145.48
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity698.58710.40584.61499.64621.66656.50298.97466.19145.48
Total Liabilities & Stockholders Equity913.17910.43780.35663.98777.33768.46344.65480.82155.37
Book Value Per Share1.702.332.282.663.964.472.373.781.99
Tangible Book Value Per Share1.021.401.392.663.964.472.373.781.99
Full-Time Employees9758385575033192411488863
Price to Book Ratio4.602.913.092.564.8210.3811.702.343.48
Return on Assets-42.88-44.02-61.49-54.93-44.28-46.64-47.86-38.85-56.26
Return on Equity-55.50-57.48-81.91-70.61-53.55-54.34-51.64-40.41-58.94
Return on Invested Capital-52.62-49.24-68.03-69.15-49.74-36.98-65.15-26.51-63.28
Quick Ratio2.833.312.705.245.6911.598.1033.0215.56
Current Ratio3.203.742.795.245.6911.598.1033.0215.56

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-220.53-390.98-372.18-444.04-395.89-342.25-259.58-197.56-123.58
Depreciation43.8847.3243.6133.1321.1413.988.718.120.96
Other Funds (Non Cash)47.3067.58100.9859.0984.8975.7842.7520.5418.70
Funds from Operations-130.60-278.14-230.42-355.30-289.87-252.49-208.12-168.90-103.92
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-59.35-24.27-122.56-6.52-2.8924.552.9810.012.67
Cash from Operating Activities-189.95-302.41-352.98-361.82-292.76-227.94-205.13-158.89-101.25
Capital Expenditures-26.20-33.84-11.07-22.29-20.43-37.57-46.79-6.92-1.20
Net Assets From Acquisitions0.000.00-52.57-212.630.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-170.3281.33-32.7779.68276.8837.71-271.0696.94-385.08
Purchase of Investments-432.32-318.67-460.77-205.90-245.82-725.21-947.66-417.66-426.08
Sale Or Maturity of Investments262.00400.00428.00285.58522.70762.91676.60514.6041.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-196.5347.50-96.41-155.24256.450.13-317.8590.03-386.28
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock294.29307.83403.52465.75192.80238.27576.426.13424.31
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock294.29307.83403.52465.75192.80238.27576.426.13424.31
Proceedsfrom Stock Options293.27307.82400.26465.69191.16204.74566.76-0.31398.59
Issuance or Reduction of Debt, Net0.000.000.000.000.001.000.000.000.00
Change in Long Term Debt0.000.000.000.000.001.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.001.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-8.21-7.06-12.86-2.79-2.650.000.000.000.00
Other Financing Activities Uses-8.21-7.06-12.86-2.79-2.650.000.000.000.00
Cash from Financing Activities286.08300.77390.66462.96190.15239.27576.426.13424.31
Exchange Rate Effect0.251.14-0.54-2.74-----
Net Change in Cash-100.1547.01-59.27-56.84153.8511.4653.44-62.73-63.22
Free Cash Flow-216.06-336.24-364.05-384.11-313.18-265.51-251.93-165.81-102.45
Deferred Taxes & Investment Tax Credit--2.07-2.83-3.480.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments376.32297.67313.44296.98300.80301.18
Short Term Receivables106.99102.1281.7682.4566.7659.94
Inventories55.2255.5958.3851.6851.7149.83
Other Current Assets11.118.8712.9311.589.8211.55
Total Current Assets549.63464.26466.50442.69429.09422.50
Net Property, Plant & Equipment171.87174.94175.78177.01175.41172.42
Total Investments and Advances6.026.005.995.985.965.94
Intangible Assets259.21263.89269.10279.32285.21296.25
Other Assets4.486.438.298.179.2710.32
Total Assets991.21915.53925.66913.17904.95907.44
Short Term Debt Incl. Current Port. of LT Debt2.442.673.905.047.288.07
Accounts Payable21.6426.2137.4522.1631.2432.00
Other Current Liabilities81.6977.9688.07111.1687.2789.08
Total Current Liabilities105.77106.85129.42138.36125.78129.16
Long Term Debt42.7743.3343.8844.4045.2145.10
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities30.0129.3130.6131.8331.6634.70
Other Liabilities0.000.000.000.000.000.00
Total Liabilities178.55179.49203.91214.59202.66208.95
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity812.66736.04721.75698.58702.28698.49
Total Shareholders Equity812.66736.04721.75698.58702.29698.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity812.66736.04721.75698.58702.29698.49
Total Liabilities & Stockholders Equity991.21915.53925.66913.17904.95907.44
Book Value Per Share1.761.621.651.701.822.04
Tangible Book Value Per Share1.201.041.031.021.081.18
Full-Time Employees---975--
Price to Book Ratio4.602.532.071.501.060.75
Return on Assets-23.26-31.76-37.40-42.88-41.94-41.66
Return on Equity-29.11-40.36-47.51-55.50-53.89-53.16
Return on Invested Capital-2.60-6.07-10.32-9.68-12.21-15.02
Quick Ratio4.673.823.152.833.002.89
Current Ratio5.204.353.603.203.413.27

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-22.27-47.31-79.05-71.90-91.25-111.66
Depreciation10.4110.4010.4112.6411.6811.94
Other Funds (Non Cash)10.1113.2810.1113.8011.8121.09
Funds from Operations-1.13-25.01-59.19-45.27-70.17-76.64
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.34-35.83-12.88-7.29-8.539.19
Cash from Operating Activities-4.47-60.84-72.07-52.56-78.70-67.45
Capital Expenditures-4.84-5.44-6.61-9.32-10.84-7.46
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-129.81-68.6118.0010.1027.8621.30
Purchase of Investments-186.81-129.61-56.00-59.91-92.14-68.70
Sale Or Maturity of Investments57.0061.0074.0070.00120.0090.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-134.65-74.0511.390.7817.0113.84
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock88.7050.4598.5156.6288.5213.73
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock88.7050.4598.5156.6288.5213.73
Proceedsfrom Stock Options87.9049.5798.5157.2988.5213.06
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-2.42-1.17-4.18-0.45-0.47-0.50
Other Financing Activities Uses-2.42-1.17-4.18-0.45-0.47-0.50
Cash from Financing Activities86.2849.2994.3356.1788.0613.23
Exchange Rate Effect0.01-0.12-0.210.58-0.680.74
Net Change in Cash-52.82-85.7333.444.9625.69-39.64
Free Cash Flow-9.21-66.28-78.68-61.88-89.55-74.91

Revenue breakdown

Amtagvi2024: 103.57M 2025: 220.02M
PROLEUKIN2024: 60.50M 2025: 43.48M
Non-US2024: 3.03M 2025: 4.49M
United States2024: 161.04M 2025: 259.01M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.19%65.2M402.7M17.28M
2026-10-1514.95%58.9M394.3M17.23M
2026-09-3016.48%64.8M393.4M17.85M
2026-09-1522.15%87.1M393.4M16.34M
2026-08-3122.40%88.1M393.4M16.51M
2026-08-1426.16%102.9M393.5M15.77M
2026-07-3125.41%100.0M393.5M15.33M
2026-07-1525.75%99.9M387.9M14.69M
2026-06-3025.92%100.5M387.9M14.59M
2026-06-1526.73%103.5M387.1M14.16M
2026-05-2926.88%104.2M387.9M15.79M
2026-05-1527.48%106.6M387.9M17.14M
2026-04-3029.95%114.7M383.0M15.69M
2026-04-1530.96%108.8M351.4M15.97M
2026-03-3131.54%110.8M351.4M15.14M
2026-03-1332.74%115.1M351.4M15.41M
2026-02-2737.26%130.9M351.4M12.99M
2026-02-1337.40%131.3M351.2M11.42M
2026-01-3031.08%105.3M338.7M14.58M
2026-01-1534.58%117.1M338.7M14.41M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.004.008.206.150.00015.000.000.957-0.2360.001
call3.004.305.905.1318.37217.000.000.934-0.2380.001
call4.002.304.404.198.69613.002.000.910-0.2320.001
call4.501.505.703.7011.6639.000.000.895-0.2250.001
call5.002.404.003.1611.1475.000.000.876-0.2150.001
call5.501.803.402.789.29210.000.000.855-0.2040.001
call6.000.154.202.3910.4753.000.000.833-0.1940.002
call6.500.103.701.9411.6991.000.000.802-0.1790.002
call7.000.003.301.6012.2834.000.000.757-0.1600.002
call7.500.002.800.6010.7354.000.000.671-0.1860.002
call8.000.000.950.503.6118810.000.574-0.1450.002
call8.500.050.150.101.3951302.000.415-0.1130.002
call9.000.000.100.102.0532410.000.278-0.1010.002
call9.500.000.050.073.3242120.000.305-0.1700.002
call10.000.000.150.101.9541,6280.000.094-0.0480.001
call10.500.000.950.052.28572.000.000.083-0.0520.001
call11.000.002.000.152.5892240.000.075-0.0540.001
call11.500.000.750.002.9370.000.000.069-0.0570.001
call12.000.002.150.153.13527.000.000.065-0.0580.001
call12.500.001.150.253.38217.000.000.061-0.0600.001
call13.000.000.753.593.6385.000.000.058-0.0620.001
call13.500.000.500.253.88039.000.000.055-0.0630.001
call14.000.002.150.204.04735.000.000.053-0.0640.001
call14.500.002.151.454.24737.000.000.051-0.0660.001
call15.000.002.150.104.43765.000.000.049-0.0670.001
call15.500.001.950.054.65150.000.000.048-0.0680.001
call16.000.002.150.104.79551.000.000.047-0.0690.001
call16.500.000.750.205.00118.000.000.045-0.0700.001
call17.000.002.150.055.12454.000.000.044-0.0710.001
call17.500.002.150.385.2994.000.000.043-0.0710.001
call18.000.000.700.155.46726.000.000.042-0.0720.001
call18.500.000.750.225.61117.000.000.041-0.0730.001
call19.000.002.150.665.72714.000.000.041-0.0740.001
call19.500.002.150.005.8480.000.000.040-0.0740.001
call20.000.002.150.205.97920.000.000.039-0.0750.001
call20.500.002.150.006.1060.000.000.039-0.0750.001
call21.000.002.150.006.2430.000.000.038-0.0760.001
call21.500.002.150.006.3760.000.000.038-0.0770.001
call22.000.002.150.306.4931.000.000.037-0.0770.000
call22.500.001.950.006.5780.000.000.037-0.0780.000
call23.000.000.950.006.7140.000.000.036-0.0780.000
call23.500.001.000.006.8490.000.000.036-0.0790.000
call24.000.002.150.006.9180.000.000.035-0.0790.000
call24.500.002.150.007.0550.000.000.035-0.0790.000
call25.000.002.150.007.1180.000.000.035-0.0800.000
call25.500.002.150.007.2150.000.000.034-0.0800.000
call26.000.002.150.007.3100.000.000.034-0.0810.000
call26.500.002.150.007.3850.000.000.034-0.0810.000
call27.000.002.150.007.4930.000.000.033-0.0810.000
call27.500.002.150.007.5910.000.000.033-0.0820.000
call28.000.002.150.007.6510.000.000.033-0.0820.000
call30.000.002.150.007.9860.000.000.032-0.0840.000
put2.000.002.100.0017.5810.000.00-0.043-0.2350.001
put3.000.002.100.0012.7990.000.00-0.065-0.2390.001
put4.000.002.100.009.6430.000.00-0.090-0.2310.001
put4.500.002.150.008.3330.000.00-0.106-0.2240.001
put5.000.002.100.007.2410.000.00-0.122-0.2160.001
put5.500.002.100.076.1996.000.00-0.143-0.2060.001
put6.000.001.000.015.14420.000.00-0.171-0.1900.002
put6.500.002.000.034.2596.000.00-0.204-0.1750.002
put7.000.001.000.071.7031.000.00-0.150-0.0500.002
put7.500.000.750.102.61172.000.00-0.331-0.1870.002
put8.000.000.350.301.71319720.00-0.426-0.1440.002
put8.500.001.050.603.42918.000.00-0.585-0.1120.002
put9.000.003.101.558.63729.000.00-0.796-0.0620.002
put9.500.603.601.507.2144.000.00-0.889-0.0430.001
put10.001.102.651.955.71210.000.00-0.906-0.0470.001
put10.500.304.500.0011.7270.000.00-0.917-0.0500.001
put11.000.804.903.1211.7973.000.00-0.925-0.0530.001
put11.501.305.500.0012.6330.000.00-0.931-0.0550.001
put12.001.805.603.4311.4011.000.00-0.935-0.0570.001
put12.502.306.504.0013.4020.000.00-0.939-0.0590.001
put13.002.807.004.9013.7511.000.00-0.942-0.0600.001
put13.503.307.505.3414.0811.000.00-0.945-0.0620.001
put14.003.808.006.1514.39222.000.00-0.947-0.0630.001
put14.504.308.507.1014.6877.000.00-0.949-0.0640.001
put15.005.009.007.5414.9462.000.00-0.951-0.0650.001
put15.505.309.507.4015.2353.000.00-0.952-0.0660.001
put16.005.8010.007.9015.4912.000.00-0.953-0.0670.001
put16.506.3010.508.3415.7351.000.00-0.955-0.0680.001
put17.007.0011.008.5815.1552.000.00-0.956-0.0690.001
put17.507.3011.509.0213.3162.000.00-0.957-0.0690.001
put18.008.9010.800.0011.3440.000.00-0.958-0.0700.001
put18.508.3012.500.0016.6170.000.00-0.959-0.0710.001
put19.008.8013.0010.5116.8171.000.00-0.959-0.0710.001
put19.509.3013.5010.9517.0101.000.00-0.960-0.0720.001
put20.009.8014.0011.7117.1972.000.00-0.961-0.0730.001
put20.5010.3014.5012.0817.3771.000.00-0.961-0.0730.001
put21.0010.8015.0012.5217.5524.000.00-0.962-0.0740.001
put21.5011.3015.5012.8716.9052.000.00-0.962-0.0740.001
put22.0012.3015.3013.5114.8022.000.00-0.963-0.0740.000
put22.5012.3016.5014.2518.0441970.00-0.963-0.0750.000
put23.0012.8017.0014.7518.1991950.00-0.964-0.0760.000
put23.5013.3017.5015.4018.3491910.00-0.964-0.0760.000
put24.0013.8018.0015.9018.4951460.00-0.965-0.0760.000
put24.5014.3018.5016.1518.63846.000.00-0.965-0.0770.000
put25.0015.5018.500.0016.7120.000.00-0.965-0.0770.000
put25.5015.3019.500.0018.8870.000.00-0.966-0.0780.000
put26.0015.8020.000.0019.0430.000.00-0.966-0.0780.000
put26.5016.3020.5018.3219.1710.000.00-0.966-0.0780.000
put27.0016.8021.0018.9219.2973410.00-0.967-0.0790.000
put27.5017.3021.5019.4219.4193410.00-0.967-0.0790.000
put28.0017.8022.000.0019.5390.000.00-0.967-0.0790.000
put30.0019.8024.000.0019.9910.000.00-0.968-0.0800.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-10SCHEDULE 13GSEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-023Initial statement of beneficial ownership of securities2026-09-30SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-07SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-028-KCurrent report2026-06-30SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-18S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.28%
MHR FUND MANAGEMENT LLC6.49%
STATE STREET CORP5.48%
TWO SIGMA INVESTMENTS, LP4.26%
VANGUARD CAPITAL MANAGEMENT LLC4.08%
VANGUARD PORTFOLIO MANAGEMENT LLC3.22%
GEODE CAPITAL MANAGEMENT, LLC2.31%
MILLENNIUM MANAGEMENT LLC1.91%
DIMENSIONAL FUND ADVISORS LP1.38%
Palo Alto Investors LP1.19%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.25%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.32%
VANGUARD SMALL-CAP INDEX FUND1.09%
Fidelity Small Cap Index Fund0.97%
VANGUARD EXTENDED MARKET INDEX FUND0.96%
iShares Russell 2000 Value ETF0.83%
VANGUARD SMALL-CAP VALUE INDEX FUND0.69%
iShares Biotechnology ETF0.61%
Nuveen Quant Small Cap Equity Fund0.61%

OakChart. IOVA. Cached 15 minutes.